Tag: pharmaceutical

Ping An Launches “Ping An Home” Service Brand

Advancing Proactive Health Management to Meet Chinese Families' Demand for Healthy LongevityHONG KONG and SHANGHAI, June 2, 2026 /PRNewswire/ -- As population aging accelerates...

Victory Square Reports Q1 2026 Financial Results and Provides Portfolio Update

Revenue Increased to $24.9 Million, Net Income Totaled $3.9 Million, and Cash & Marketable Securities Increased to Approximately $31 Million VANCOUVER, BC, June 1, 2026...

Hydreight Delivers Record First Quarter 2026 Revenue of $24.9 Million with 449% Revenue Growth, $3.3 Million in Adjusted EBITDA² and $32.0 Million in Working...

Revenue increased 449% year-over-year while the Company continued to scale its healthcare infrastructure platform. VANCOUVER, BC and LAS VEGAS, June 1, 2026 /CNW/ - Hydreight...

Shear Media Studios Expands 11,000 Sq. Ft. Tampa Bay Production Facility for Studio Rentals, Podcasts, Commercials, Film, and Broadcasts

ST. PETERSBURG, Fla., May 21, 2026 /PRNewswire/ -- Shear Media Studios is expanding its 11,000 sq. ft. Tampa Bay production facility to meet growing...

Rakovina Therapeutics Announces Q1 2026 Financial Results and Provides Corporate Update

All dollar amounts reflected in Canadian dollars unless otherwise stated.

West Appoints Michel Lagarde to be President and Chief Executive Officer

Experienced healthcare and life sciences executive to lead the Company's next phase of growth and innovationEXTON, Pa., June 1, 2026 /PRNewswire/ -- West Pharmaceutical...

Phenomenex Launches Endrix Long Life Columns, Redefining Column Durability and Method Reliability

Redefined Column Durability and Method ReliabilityTORRANCE, Calif., June 1, 2026 /PRNewswire/ -- Phenomenex Inc., a Danaher Company and a global leader in the research...

Ascentage Pharma Announces Global Registrational Phase III Study of Lisaftoclax for First-line Treatment of Patients with Higher-Risk Myelodysplastic Syndrome Cleared by US FDA and...

ROCKVILLE, Md. and SUZHOU, China, Aug. 17, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced that it has received clearance by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) to conduct GLORA-4 study (NCT06641414), a global registrational Phase III study of lisaftoclax (APG-2575), a proprietary Bcl-2 inhibitor, in combination with azacitidine (AZA), for the treatment of patients with newly diagnosed higher-risk myelodysplastic syndrome (HR-MDS).

HIMS IMPORTANT DEADLINE: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Hims & Hers Health, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before...

NEW YORK, Aug. 17, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Hims & Hers Health, Inc. (NYSE: HIMS) between April 29, 2025 and June 23, 2025, both dates inclusive (the “Class Period”), of the important August 25, 2025 lead plaintiff deadline.

BRBR LOSS ALERT: BellRing Brands, Inc. Investors with Losses are Reminded of the Ongoing Securities Fraud Investigation – Contact BFA Law (NYSE:BRBR)

BellRing Brands, Inc. investors that lost money are notified to contact BFA Law about its ongoing securities fraud class action investigation.

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Hims & Hers Health

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Hims To Contact Him Directly To Discuss Their Options

Hims & Hers (HIMS) Drops Amid Reported Details of FTC Investigation, Adding To Investor Scrutiny In Pending Securities Class Action – Hagens Berman

SAN FRANCISCO, Aug. 15, 2025 (GLOBE NEWSWIRE) -- On August 14, 2025 the price of Hims & Hers Health (NYSE: HIMS) shares significantly dropped in after-hours trading after the financial press reported that the FTC is probing the company’s advertising practices and whether it makes it too difficult for customers to cancel subscriptions.

Allarity Therapeutics Provides Second Quarter 2025 Update, Highlighting Clinical Progress, IP Expansion, and New Partnerships

- Successfully initiated enrollment in advanced Phase 2 ovarian cancer trial

Tonix Pharmaceuticals Announces FDA Approval of Tonmya™ (cyclobenzaprine HCl sublingual tablets) for the Treatment of Fibromyalgia

Tonmya is the first FDA-approved therapy for the treatment of fibromyalgia in over 15 years

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Company Name

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

Phone

This field is for validation purposes and should be left unchanged.

HomeTagsPharmaceutical

Orbis International’s Flying Eye Hospital Arrives in Peru to Expand Access to Essential Eye Care

Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026)

Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026 Congress